Abstracts tagged "rheumatoid arthritis (RA) and severity"

Abstract Number: 470 • 2017 ACR/ARHP Annual Meeting
Clinical Response to the First Biologic in Rheumatoid Arthritis Patients with Moderate Disease in a Real World Clinical Cohort
Xiuying Li, Angela Cesta, Mohammad Movahedi and Claire Bombardier, Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada
Background/Purpose: While most randomized trials assess the effectiveness of biologic DMARDs (bDMARDs) in rheumatoid arthritis (RA) patients with high disease activity, in the real world…
Abstract Number: 99 • 2015 ACR/ARHP Annual Meeting
Personalised Genetic Medicine: HLA-DRB1 Amino Acid Positions 11, 71 and 74 Predict Inflammation Level, Disease Activity and Disability in Rheumatoid Arthritis
Stephanie Ling¹, Sebastien Viatte², Mark Lunt³, Alper van Sijl⁴, Lucía Silva Fernández^4,5, Soumya Raychaudhuri^2,6,7, Deborah P.M. Symmons^4,8, Adam Young^9,10, Alex J Macgregor¹¹ and Anne Barton¹², ¹Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Mancheser Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, ²Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, ³Manchester Academic Health Sciences Centre, Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ⁴Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, ⁵Rheumatology, Complexo Hospitalario Universitario de Ferrol, Ferrol, Spain, ⁶Divisions of Rheumatology and Genetics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁷Medical and Population Genetics Program, Broad Institute of MIT and Harvard, Cambridge, MA, ⁸Centre for Musculoskeletal Research, University of Manchester, Arthritis Research UK Centre for Epidemiology, Manchester, United Kingdom, ⁹Rheumatology, ERAS, St Albans City Hospital, St Albans, United Kingdom, ¹⁰School of Life & Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom, ¹¹School of Medicine, Health Policy and Practice, University of East Anglia, Norwich, United Kingdom, ¹²Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, The University Of Manchester, Manchester, United Kingdom
Background/Purpose: Amino acid (AA) positions 11, 71 and 74 inside HLA-DRB1 confer susceptibility to rheumatoid arthritis (RA). AAs from these positions form 16 haplotypes, hierarchically…
Abstract Number: 3100 • 2015 ACR/ARHP Annual Meeting
Anti-RA33 Citrullinated/Native Double-Reactive Antibodies Identify Patients with the Highest Risk of Radiographic Progression in Rheumatoid Arthritis
Maximilian F. Konig¹, Jon Giles², Peter A. Nigrovic³ and Felipe Andrade¹, ¹Division of Rheumatology, The Johns Hopkins University School of Medicine, Baltimore, MD, ²Rheumatology, Columbia University Medical Center, NY, NY, ³Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Antibodies against RA33 (hnRNP A2/B1) were one of the earliest antigen specificities identified in rheumatoid arthritis (RA). Unlike the erosive disease associated with anti-citrullinated…
Abstract Number: 1140 • 2014 ACR/ARHP Annual Meeting
Association of Polymorphisms on OPG, RANK and RANKL with ACPA Presence and Erosions: Results of a Meta-Analysis on 1570 Rheumatoid Arthritis Patients from 3 French Cohorts
Adeline Ruyssen Witrand^1,2,3, Sara Scaramuzzino^1,2, Delphine Nigon⁴, Cédric Lukas⁵, Yannick Allanore⁶, Olivier Vittecoq⁷, Thierry Schaeverbeke⁸, Jacques Morel⁹, Jean Sibilia¹⁰, Anne Cambon-Thomsen^1,2, Alain G. Cantagrel¹¹, Philippe Dieude^12,13 and Arnaud Constantin⁴, ¹UMR 1027, Inserm, Toulouse, France, ²UMR 1027, University Paul Sabatier, Toulouse, France, ³Rheumatolgy, CHU Purpan - Hôpital Pierre-Paul Riquet, Toulouse, France, ⁴Rheumatology, CHU Purpan - Hôpital Pierre-Paul Riquet, Toulouse, France, ⁵Immuno-Rhumatologie, Hopital Lapeyronie, Montpellier, France, ⁶Department of Rheumatology, University Paris Descartes and Cochin Hospital, Paris, France, ⁷Rheumatology, Department of Rheumatology, Rouen University Hospital & Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen, France, ⁸Rheumatology, Bordeaux University Hospital, Bordeaux, France, ⁹Department of Rheumatology, Hôpital Lapeyronie, Montpellier, France, ¹⁰Division of Rheumatology, University Hospital of Strasbourg, Strasbourg, France, ¹¹Centre Hospitalier Universitaire de Toulouse, Toulouse, France, ¹²Rheumatology, Rheumatology departement & INSERM U699, Paris Diderot university, APHP, Bichat hospital, Paris, France, ¹³Rhumatologie, Hopital Bichat Claude Bernard, Paris, France
Background/Purpose Rheumatoid Arthritis (RA) is a multifactorial complex disease characterized by the presence of anti-citrullinated peptides antibodies (ACPA) and joints erosions. The mechanisms of bone…
Abstract Number: 174 • 2013 ACR/ARHP Annual Meeting
Genetic Association On Disease Severity In Rheumatoid Arthritis: A Validation Study In Japanese Patients
Shinji Yoshida¹, Katsunori Ikari¹, Koichiro Yano¹, Yoshiaki Toyama², Atsuo Taniguchi³, Hisashi Yamanaka¹ and Shigeki Momohara³, ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Department of Orthopaedic Surgery, Keio University School of Medicine, Tokyo, Japan, ³Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose: The disease severity of rheumatoid arthritis (RA) is objectively measured by radiographic joint destruction, which is reflective of the cumulative burden of inflammation. Recently,…
Abstract Number: 2670 • 2012 ACR/ARHP Annual Meeting
Genome-Wide Association Study On the Severity of Joint Destruction in Autoantibody Positive Rheumatoid Arthritis Identifies a Role for Sperm Associated Antigen 16
Rachel Knevel¹, Kerstin Klein², Klaartje Somers³, Caroline Ospelt⁴, Jeanine J. Houwing-Duistermaat⁵, Jessica van Nies⁶, Diederik P.C. de Rooy⁶, Laura de Bock⁷, Joris Schonkeren⁸, Gerrie Stoeken-Rijsbergen⁶, Jenna Kiridly⁹, Luis Rodriguez-Rodriguez⁹, Quinta Helmer⁵, Piet Sinissen³, Tom W. J. Huizinga¹, René E.M. Toes¹, Steffen Gay¹⁰, Peter K. Gregersen¹¹, Veerle Somers⁷ and Annette H.M. van der Helm - van Mil⁸, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Center of Experimental Rheumatology, University Hospital Zurich and Zurich Center of Integrative Human Physiology (ZIHP),, Zurich, Switzerland, ³Hasselt University, Biomedical Research Institute, Diepenbeek, Belgium, ⁴Center of Experimental Rheumatology, University Hospital Zurich and Zurich Center of Integrative Human Physiology (ZIHP), Switzerland, Zurich, Switzerland, ⁵Department of Medical Statistics and Bioinformatics, Leiden, Netherlands, ⁶Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁷Hasselt University, Biomedical Research Institute, Belgium, ⁸Leiden University Medical Center, Leiden, Netherlands, ⁹Feinstein Institute for Medical Research and North Shore–Long Island Jewish Health System, Manhasset, New York, ¹⁰Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, ¹¹Genomics and Human Genetics, Feinstein Institute for Medical Research, Manhasset, NY
Background/Purpose: Recent genome-wide association studies (GWAs) have identified >30 SNPs predisposing to Rheumatoid Arthritis (RA). These variants are helpful in unraveling the pathogenesis of RA.…
Abstract Number: 2146 • 2012 ACR/ARHP Annual Meeting
Impact of Severity Index for Rheumatoid Arthritis On Healthcare Costs and Utilizations in Patients with Rheumatoid Arthritis
Onur Baser¹, Li Wang², Juan Du³, Hai Wang³ and Lin Xie⁴, ¹President/Adjunct Professor of Internal Medicine, STATinMED Research/The University of Michigan, Ann Arbor, MI, ²Director, Analytic Research, STATinMED Research, Dallas, TX, ³STATinMED Research, Ann Arbor, MI, ⁴Director, Health Economics & Outcomes Research, STATinMED Research, Ann Arbor, MI
Background/Purpose: Examine the impact of a claims-based severity index for rheumatoid arthritis (RA) on healthcare costs and utilizations of RA patients using large U.S. claims…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].